Scott Gottlieb is stepping down as leader of the FDA — and many in health and medicine quickly turned to Twitter to express their displeasure.

Gottlieb, who has served as the commissioner of the Food and Drug Administration since May 2017, announced on Tuesday that he plans to leave his post in one month. During his tenure, the FDA broke annual records for generic drug approvals, cracked down on unproven stem cell treatments, and took new steps to curb youth e-cigarette use.

“This has been a wonderful journey and parting is very hard,” he said in a tweet of his own, adding that he was “immensely grateful for the opportunity to help lead this wonderful agency.”


His work quickly won Gottlieb respect from lawmakers in both parties and made him one of President Trump’s most popular appointees, though some consumer advocates argued that he wasn’t tough enough in regulating the drug and tobacco industries.

Some in the public health and health policy communities praised his work on vaping, drug pricing, and other issues.

Others said they would miss his approach to overseeing drug approvals and his efforts to publicly promote vaccinations.

But he also faced criticism for not acting aggressively enough to address the rise in vaping among teens, for the agency’s controversial approval of a new opioid painkiller, and for being too close to the pharmaceutical industry.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy